RON directly interacts with IRAK4 to inhibit its pro-inflammatory effects in the TLR signaling pathway which suppresses type I interferon (IFN-I) signaling and thereby prevents activation of the anti-tumor response by innate immune cells [35]. Here, IRAK4 is linked to neoplasm.